pembrolizumab
merck
['pembro', 'mbc', 'lymsm']
congress| #asco23 andrew mcdonald evaulates clinical trial assessing safety and efficacy of pembrolizumab in patients with r/r chl and pmbcl. these data 9 months post analysis confirmed q6w dosing in these patients had no new safety concerns with robust antitumor activity #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm